삼성바이오에피스, 체질전환 키 '병원 데이터'…ADC 임상 변수 완충

Samsung BioePis is leveraging Samsung Seoul Hospital's medical data to accelerate its shift from biosimilar-focused business to innovative drug development, particularly for ADC candidates. This strategic partnership is significant because clinical data directly reduces uncertainties in patient selection, safety management, and early-stage pipeline validation—critical factors where biosimilar development differs from new drug innovation. The collaboration demonstrates how healthcare data infrastructure becomes competitive advantage in managing development risks and fast-tracking clinical strategy refinement.